Core Viewpoint - The article discusses the adjustment of the Wanfu convertible bond, highlighting its implications for investors and the market dynamics surrounding convertible bonds [1]. Group 1: Convertible Bond Adjustments - Wanfu convertible bond (code: 123064) has announced an adjustment, with the announcement date set for January 14, 2026 [2]. - The adjustment is part of a broader trend in the convertible bond market, where issuers are modifying terms to enhance attractiveness to investors [1]. Group 2: Market Data on Convertible Bonds - Various convertible bonds are listed with their current prices, redemption prices, last trading dates, last conversion dates, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [4][6]. - For instance, the Kai Sheng convertible bond (code: 123233) has a current price of 141.461, a redemption price of 100.100, and a conversion value of 141.58, with a remaining scale of 0.007 billion [4]. - The Liu Yao convertible bond (code: 113563) has a current price of 107.926, a redemption price of 108.000, and a conversion value of 87.77, with a remaining scale of 8.010 billion [6]. Group 3: Company Earnings Forecasts - Companies such as Shanhe Pharmaceutical and Jinyu Jidong have provided earnings forecasts for 2025, with Shanhe expecting a profit of 165 million to 194 million, representing a year-on-year growth of 38.16% to 62.45% [8]. - Jinyu Jidong anticipates a profit of 180 million to 260 million for the same period [8].

（文章来源：证券日报） 证券日报网讯 1月14日，万孚生物发布公告称，公司第五届董事会第二十一次会议审议通过《关于向下 修正"万孚转债"转股价格的议案》。 ...

（编辑 丛可心） 证券日报网讯 1月14日，万孚生物发布公告称，公司决定将"万孚转债"转股价格由27.00元/股向下修正 为21.10元/股，预计2026年1月15日生效。触发条件为2025年12月9日至29日连续三十个交易日中至少十 五个交易日收盘价低于当期转股价80%（21.60元/股），公司已履行董事会及股东大会审议程序。 ...

Group 1 - Wanfu Convertible Bond proposes a down adjustment [1] - Hongtu Convertible Bond adjusts but does not lower the adjustment period [1] - Oulutong's controlling shareholder plans to reduce holdings by no more than 1.91% of the company's shares [1] - Unisplendour plans to acquire shares of Ruineng Semiconductor, leading to a stock suspension [1] Group 2 - Hongchuan Convertible Bond announced a down adjustment [2] - Hongtu Convertible Bond will not lower the adjustment period [2] - Wanfu Convertible Bond proposes a down adjustment [2] - Baolai Convertible Bond will not undergo a down adjustment [2] Group 3 - Various convertible bonds listed with current prices, redemption prices, last trading dates, last conversion dates, conversion values, remaining scales, and the proportion of convertible bonds to underlying stocks [4][6] - For example, Yingbo Convertible Bond has a current price of 142.440, a redemption price of 100.100, and a conversion value of 142.56 with a remaining scale of 1.103 billion [4] - Liuyao Convertible Bond has a current price of 107.862, a redemption price of 108.000, and a conversion value of 83.85 with a remaining scale of 8.017 billion [6] Group 4 - Quick query highlights include Hongchuan Convertible Bond's adjustment not reaching the bottom and Baolai Convertible Bond not undergoing a down adjustment [8]

Group 1 - Company Jiutian Pharmaceutical plans to invest no more than 400 million yuan to acquire the patent and technology for the small molecule analgesic drug YJ2301 from Suzhou Yuanju [1] - The last trading day for Jian Gong Convertible Bond is set for December 16, 2025 [1] - The proportion of convertible bonds held by Youmeili Investment Management in Wanfu Convertible Bond has reached 20%, with a total of 1,230,467 bonds held as of December 11, 2025, accounting for 20.51% of the total issuance [1] Group 2 - Shengxun Convertible Bond will not undergo a downward adjustment [2] - New stocks from Xihua Technology and Tianmo Measurement are available for subscription [2] - The listing of Ruike Convertible Bond has been confirmed [2] Group 3 - Various convertible bonds are listed with their current prices, redemption prices, last trading days, last conversion days, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [5][7]

Core Viewpoint - Wanfu Biological (300482.SZ) has received a notification from Shenzhen Youmeili Investment Management Co., Ltd., indicating that as of the market close on December 11, 2025, Youmeili Investment manages a total of 1,230,467 "Wanfu Convertible Bonds," accounting for 20.51% of the total issuance of the company's convertible bonds [1] Group 1 - The total number of "Wanfu Convertible Bonds" held by Youmeili Investment is 1,230,467 [1] - Youmeili Investment's holdings represent 20.51% of the total issuance of the company's convertible bonds [1]

Core Viewpoint - Wanfu Biological (300482.SZ) has received a notification from Shenzhen Youmeili Investment Management Co., Ltd., indicating that as of the market close on December 11, 2025, Youmeili Investment's securities investment funds hold a total of 1,230,467 "Wanfu Convertible Bonds," accounting for 20.51% of the total issuance of the company's convertible bonds [1] Summary by Category - **Company Holdings** - Youmeili Investment holds 1,230,467 convertible bonds of Wanfu Biological [1] - This holding represents 20.51% of the total issuance of Wanfu's convertible bonds [1]

Group 1 - The company announced that the board has agreed to adjust the period for the downward revision of the conversion price of "Wanfang Convertible Bonds" from "October 22, 2025, to January 21, 2026" to "October 22, 2025, to December 8, 2025" [2] - The next period for triggering the downward revision of the conversion price is expected to restart from December 9, 2025 [2] - If the conditions for the downward revision of the conversion price are triggered again, the company will follow relevant procedures to decide whether to exercise the right to downwardly revise the conversion price of "Wanfang Convertible Bonds" [2]

Core Viewpoint - The China Convertible Bond Index experienced a decline of 0.36%, closing at 482.17 points on December 9, indicating a downward trend in the convertible bond market [1][2]. Performance Summary Top Gainers - Fu Rong Convertible Bond (福蓉转债) increased by 8.33%, reaching a price of 179.692 [2][3]. - Hu Gong Convertible Bond (沪工转债) rose by 7.29%, with a price of 150.978 [2][3]. - Wanfu Convertible Bond (万孚转债) saw a gain of 4.31%, priced at 124.01 [2][3]. - Wei Dao Convertible Bond (微导转债) climbed by 4.22%, reaching 320.031 [2][3]. Top Losers - Rui Da Convertible Bond (瑞达转债) fell by 9.61%, with a price of 148.234 [2][3]. - Yu Guang Convertible Bond (豫光转债) decreased by 4.63%, priced at 182.6 [2][3]. - Zhong Neng Convertible Bond (中能转债) dropped by 3.83%, reaching a price of 175.99 [2][3].

Core Viewpoint - The article discusses the final trading day of the Eagle 19 convertible bond, highlighting its premium and trading performance, as well as other related convertible bonds and their market conditions [1]. Group 1: Eagle 19 Convertible Bond - The Eagle 19 convertible bond is set to have its last trading day tomorrow, with a premium exceeding 10% [1]. - The closing price of the Eagle 19 convertible bond is reported at 112.622, with a redemption price of 111.000 and a conversion value of 97.16 [9]. - The remaining scale of the Eagle 19 convertible bond is 0.785 billion, representing 0.73% of the underlying stock [9]. Group 2: Other Convertible Bonds - The Wanfu convertible bond will not have its downwards adjustment period reset, effective from December 9, 2025 [3]. - The Hongtu convertible bond will not undergo a downward adjustment [3]. - The last trading day for the Liu Pharmaceutical convertible bond is January 12, 2026 [3]. Group 3: Major Holders of Convertible Bonds - The largest holder of convertible bonds is Qingdao Guanlan Investment Management Co., holding 127.94 million shares [2]. - Other significant holders include China Merchants Bank and Industrial and Commercial Bank of China, with holdings of 81.96 million and 73.74 million shares, respectively [2].